ea0063p1092 | Pituitary and Neuroendocrinology 3 | ECE2019
Solak Mirsala
, Haxhiu Arta
, Haxhiu Arita
, Kraljevic Ivana
, Dusek Tina
, Leskovar Dunja
, Polovina Tanja Skoric
, Balasko Annemarie
, Kastelan Darko
Aim: Dopamine agonist (DA) therapy is recommended as first-line treatment for prolactinomas, albeit with long treatment duration and high recurrence rate after treatment withdrawal. The aim of this retrospective study was to evaluate predictors for successful DA withdrawal.Methods: The study included 59 prolactinoma patients (39 female, 20 male; age 34 (1882) years) that were treated with DA (35.6% on cabergoline); the duration of treatment was 71 ...